Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
refametinib (BAY86-9766)
i
Other names:
BAY86-9766, BAY869766, AR 119, AR-119, AR119, BAY-86-9766, BAY 869766, RDEA 119, RDEA-119, RDEA119, AY-869766, AY 869766, AY869766, VRX-119, VRX 119, VRX119
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(16)
News
Trials
Company:
AstraZeneca
Drug class:
MEK inhibitor, ERK2 inhibitor
Related drugs:
‹
trametinib (330)
selumetinib (106)
binimetinib (68)
PD-0325901 (30)
VS-6766 (27)
CI-1040 (15)
HL-085 (12)
AS703026 (5)
CH4987655 (3)
DS03090629 (3)
LNP3794 (3)
IMM-6-415 (2)
AZD8330 (1)
PD98059 (1)
BI 847325 (0)
GDC-0623 (0)
antroquinonol (0)
MEK Inhibitor (0)
MG-D-1509 (0)
NFX-179 (0)
PF-07799544 (0)
WX-554 (0)
NSC311152 (0)
SNR1611 (0)
BVD-523 (17)
ASN007 (13)
VTX-11e (5)
JSI-1187 (4)
ASTX029 (4)
LTT462 (3)
LY3214996 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
MK-8353 (0)
ATG-017 (0)
trametinib (330)
selumetinib (106)
binimetinib (68)
PD-0325901 (30)
VS-6766 (27)
CI-1040 (15)
HL-085 (12)
AS703026 (5)
CH4987655 (3)
DS03090629 (3)
LNP3794 (3)
IMM-6-415 (2)
AZD8330 (1)
PD98059 (1)
BI 847325 (0)
GDC-0623 (0)
antroquinonol (0)
MEK Inhibitor (0)
MG-D-1509 (0)
NFX-179 (0)
PF-07799544 (0)
WX-554 (0)
NSC311152 (0)
SNR1611 (0)
BVD-523 (17)
ASN007 (13)
VTX-11e (5)
JSI-1187 (4)
ASTX029 (4)
LTT462 (3)
LY3214996 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
MK-8353 (0)
ATG-017 (0)
›
Associations
(16)
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS G13D
Hepatocellular Cancer
KRAS G13D
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS Q61H
Hepatocellular Cancer
KRAS Q61H
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS A146T
Hepatocellular Cancer
KRAS A146T
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS G12V
Hepatocellular Cancer
KRAS G12V
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS G12S
Hepatocellular Cancer
KRAS G12S
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS G12R
Hepatocellular Cancer
KRAS G12R
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS G12D
Hepatocellular Cancer
KRAS G12D
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS G12C
Hepatocellular Cancer
KRAS G12C
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS G12A
Hepatocellular Cancer
KRAS G12A
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
NRAS Q61R
Hepatocellular Cancer
NRAS Q61R
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
NRAS Q61L
Hepatocellular Cancer
NRAS Q61L
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
NRAS Q61K
Hepatocellular Cancer
NRAS Q61K
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
NRAS Q61H
Hepatocellular Cancer
NRAS Q61H
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
BRAF V600E
Thyroid Gland Carcinoma
BRAF V600E
Thyroid Gland Carcinoma
BAY86-9766
Sensitive: D – Preclinical
BAY86-9766
Sensitive
:
D
BAY86-9766
Sensitive: D – Preclinical
BAY86-9766
Sensitive
:
D
BRAF V600E
Thyroid Gland Carcinoma
BRAF V600E
Thyroid Gland Carcinoma
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
temsirolimus + BAY86-9766
Sensitive
:
D
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
temsirolimus + BAY86-9766
Sensitive
:
D
PIK3CA H1047R
Thyroid Gland Carcinoma
PIK3CA H1047R
Thyroid Gland Carcinoma
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
temsirolimus + BAY86-9766
Sensitive
:
D
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
temsirolimus + BAY86-9766
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login